How did Castle Biosciences' revenue and expenses trend in Q4 2024?

In Q4 2024, Castle Biosciences showed strong revenue growth and effective cost management, resulting in improved profitability. 1. **Revenue Trend**: The company's total revenue for Q4 2024 was $86.31 million. This represents a significant increase from the previous quarter, indicating a strong market performance and successful product sales. 2. **Expense Management**: Castle Biosciences maintained a high gross margin of 81.87%, which is a testament to efficient cost control and the company's ability to keep expenses in check relative to its revenue. The R&D expenses were $11.77 million, which is a key indicator of the company's ongoing investment in innovation and product development. The SG&A (Selling, General, and Administrative) expenses were not provided, but the focus on R&D suggests a strategic emphasis on advancing the company's pipeline rather than expanding administrative costs. 3. **Profitability**: The net income for Q4 2024 was $9.59 million, which is a direct result of the revenue growth and cost management. This positive trend is a sign of the company's financial health and its ability to generate profits from its operations. |code|Ticker|Name|Date|R&D Expenses|Gross Profit|Total Revenue|Net Income|market_code| |---|---|---|---|---|---|---|---|---| |CSTL|CSTL.O|Castle Biosciences|2023 Q4|1.2994E7|5.3697E7|6.612E7|-2580000|185| |CSTL|CSTL.O|Castle Biosciences|2024 Q1|1.3809E7|5.908E7|7.2974E7|-2534000|185| |CSTL|CSTL.O|Castle Biosciences|2024 Q2|1.4136E7|7.2483E7|8.7002E7|8920000|185| |CSTL|CSTL.O|Castle Biosciences|2024 Q3|1.2323E7|7.0173E7|8.5782E7|2269000|185|